Aisling Capital Management’s Monte Rosa Therapeutics GLUE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $6.64M | Hold |
1,472,331
| – | – | 1.85% | 4 |
|
|
2025
Q1 | $6.83M | Hold |
1,472,331
| – | – | 2.37% | 5 |
|
|
2024
Q4 | $10.2M | Hold |
1,472,331
| – | – | 3.63% | 4 |
|
|
2024
Q3 | $7.8M | Hold |
1,472,331
| – | – | 2.99% | 6 |
|
|
2024
Q2 | $5.51M | Hold |
1,472,331
| – | – | 2.38% | 7 |
|
|
2024
Q1 | $10.4M | Hold |
1,472,331
| – | – | 3.51% | 6 |
|
|
2023
Q4 | $8.32M | Hold |
1,472,331
| – | – | 2.48% | 6 |
|
|
2023
Q3 | $7.05M | Hold |
1,472,331
| – | – | 2.91% | 6 |
|
|
2023
Q2 | $10.1M | Hold |
1,472,331
| – | – | 4.94% | 5 |
|
|
2023
Q1 | $11.5M | Hold |
1,472,331
| – | – | 5.52% | 5 |
|
|
2022
Q4 | $11.2M | Hold |
1,472,331
| – | – | 7.4% | 4 |
|
|
2022
Q3 | $12M | Hold |
1,472,331
| – | – | 7.99% | 4 |
|
|
2022
Q2 | $14.2M | Hold |
1,472,331
| – | – | 10.16% | 3 |
|
|
2022
Q1 | $20.6M | Hold |
1,472,331
| – | – | 11.14% | 2 |
|
|
2021
Q4 | $30.1M | Hold |
1,472,331
| – | – | 10.61% | 2 |
|
|
2021
Q3 | $32.8M | Hold |
1,472,331
| – | – | 6.54% | 2 |
|
|
2021
Q2 | $33.4M | Buy |
+1,472,331
| New | +$33.4M | 5.35% | 3 |
|